Intrapatient dose escalation to 800 mg/m<sup>2</sup> pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapy
J. S. Lee(Seoul National University), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cheng‐yan Yang(Seoul National University), D. S. Heo(Seoul National University), G. C. Chang(Seoul National University), K. Park(Seoul National University), S. W. Kim(Seoul National University), William H. H. Reece(John Radcliffe Hospital), Te‐Chun Hsia(China Medical University), Hüseyin Yıldırım(Mersin Üniversitesi)
Cited by 0
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388